Search

Cristiane Giacomelli da Costa,1,* Mehrsa Jalalizadeh,1,* Reza Yadollahvandmiandoab,1 Keini Buosi,1 Leonardo O Reis1,2 1Department of UroScience, School of Medical Sciences, University of Campinas – UNICAMP, Campinas, São Paulo, Brazil; 2Pontifical Catholic University of Campinas, PUC, Campinas, São Paulo, Brazil*These authors contributed equally to this workCorrespondence: Leonardo O Reis, Department of UroScience, School of Medical Sciences, University of Campinas, UNICAMP, Campinas, São Paulo, Brazil, Tel +55 19 35217481, Email Reisleo@unicamp.brIntroduction: Bacillus Calmette–Guérin (BCG) has been shown to have protective effects against respiratory viruses. We conducted a scoping review of the literature to clarify the available evidence regarding the effect of BCG therapy in preventing respiratory complications of coronavirus disease 2019 (COVID-19).Methods: We searched PubMed, Embase, CENTRAL, Scopus, and Web of Science for related studies up to October 2022.Results: In total, 35 publications and trials were included. One animal study, two observational studies, and six finalized trials measured the effect of BCG administration on respiratory complications of COVID-19. The remaining publications included eight unfinished trials, 12 ecological studies, and six observational studies that did not directly measure respiratory complications but assessed overall mortality of the disease and were included as an adjunct to our study. All trials involved vaccinating adults to protect them against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and measured respiratory symptoms or the need for intensive respiratory support as the primary or secondary aim of the study. One trial that exclusively included at-risk adults between 18 and 60 years old showed a decreased chance of respiratory complications as the secondary outcome of the study. Another trial that exclusively evaluated this effect on the elderly (60 years

Patricia AF Leme,1,* Mehrsa Jalalizadeh,1,* Cristiane Giacomelli da Costa,1,* Keini Buosi,1 Luciana SB Dal Col,1 Franciele AV Dionato,1 Lucas M Gon,2 Reza Yadollahvandmiandoab,1 Leonardo O Reis1,2 1UroScience, School of Medical Sciences, University of Campinas, UNICAMP, Campinas, Sao Paulo, Brazil; 2Pontifical Catholic University of Campinas, PUC, Campinas, Sao Paulo, Brazil*These authors contributed equally to this workCorrespondence: Leonardo O Reis, UroScience, School of Medical Sciences, University of Campinas, UNICAMP, Campinas, Sao Paulo, Brazil, Tel +55 19 35217481, Email Reisleo@unicamp.brAim: To find whether an emergent airborne infection is more likely to spread among healthcare workers (HCW) based on data of SARS-CoV-2 and whether the number of new cases of such airborne viral disease can be predicted using a method traditionally used in weather forecasting called Autoregressive Fractionally Integrated Moving Average (ARFIMA).Methods: We analyzed SARS-CoV-2 spread among HCWs based on outpatient nasopharyngeal swabs for real-time polymerase chain reaction (RT-PCR) tests and compared it to non-HCW in the first and the second wave of the pandemic. We also generated an ARFIMA model based on weekly case numbers from February 2020 to April 2021 and tested it on data from May to July 2021.Results: Our analysis of 8998 tests in the 15 months period showed a rapid rise in positive RT-PCR tests among HCWs during the first wave of pandemic. In the second wave, however, positive patients were more commonly non-HCWs. The ARFIMA model showed a long-memory pattern for SARS-CoV-2 (seven months) and predicted future new cases with an average error of ± 1.9 cases per week.Conclusion: Our data indicate that the virus rapidly spread among HCWs during the first wave of the pandemic. Review of published literature showed that this was the case in multiple other areas as well. We therefore suggest strict policies early in the emergence of a new